The Top 5 Biosimilars Articles for the First Half of 2019
The Center for Biosimilars® recaps the 5 most-read stories of 2019 to date.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
It’s been a busy year for biosimilars, and this week, we’re recapping the 5 most-read stories of 2019 to date.
Number 5: The year opened with price hikes to a number of prescription drugs.
Number 4: The FDA approved another biosimilar trastuzumab product referencing Herceptin.
Number 3: Biosimilar developer Pfizer confirmed that it had cut 5 preclinical biosimilar programs from its portfolio.
Number 2: The FDA released its long-awaited final guidance on demonstrating interchangeability.
Number 1: The FDA approved Samsung Bioepis’ trastuzumab biosimilar.
What will the second half of the year hold for biosimilars? Stay up to date with the key news as it unfolds at centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
